Posted in | News | Nanomedicine

Dr. Fetzer to Highlight Nanopharmaceutical Advancement at BioPharm America Event

Cerulean Pharma Inc., a leader in nanopharmaceuticals, today announced that the Company’s chief executive, Oliver Fetzer, Ph.D., will present at the BioPharm America(TM) conference being held in Boston, Massasachusetts, from September 15-17, 2010.

The premier pharmaceutical partnership conference has joined forces with MassBio Investors Forum to bring together pharmaceutical industry executives and life science investors for one of the largest and most productive partnering events. Dr. Fetzer will brief attendees on Cerulean’s key accomplishments and positive momentum.

A key accomplishment that Dr. Fetzer will highlight is the Company’s initiation of a multi-site Phase 2a clinical study of its first-in-class nanopharmaceutical, CRLX101, in advanced cancer patients. Findings from Cerulean’s Phase 1 study with CRLX101 demonstrated clinical activity in several patients and a favorable safety profile. These data were presented at the recent 2010 American Chemical Society National Meeting & Exposition held last month in Boston, Massachusetts.

Dr. Fetzer will also describe the advancement of the Company’s lead pre-clinical candidate, CRLX288, a novel docetaxel nanopharmaceutical. Docetaxel is one of the most widely prescribed oncology drugs and is efficacious in many solid tumors. CRLX288 has been designed to further enhance the efficacy of docetaxel by maximizing drug exposure in cancer cells while at the same time minimizing bone marrow toxicity, neurotoxicity, and drug resistance, which are some of docetaxel’s clinical limitations.

“Cerulean is leading the industry with CRLX101’s progression as a first-in-class nanopharmaceutical into Phase 2a development, which speaks to the strength of our platform,” said Dr. Fetzer. “Last month we presented data showing that our nanoparticles are stable in the bloodstream, preferentially accumulate in target disease tissues, penetrate deeply in tumors, and are taken up by cancer cells. Cerulean’s nanopharmaceutical platform is unique in realizing these biological benefits, making it of keen interest to pharmaceutical companies and investors in cancer drug development, as well as in other therapeutic areas such as inflammation. We are excited about the progress Cerulean has made validating the nanopharmaceutical platform pre-clinically and increasingly in the clinic.”

Dr. Fetzer will present at 9:00 a.m. on Friday, September 17, in the Clarendon Room in Marriott Boston Copley, Boston, Massachusetts.

Source: http://www.ceruleanrx.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cerulean Pharma. (2019, February 13). Dr. Fetzer to Highlight Nanopharmaceutical Advancement at BioPharm America Event. AZoNano. Retrieved on October 03, 2024 from https://www.azonano.com/news.aspx?newsID=19548.

  • MLA

    Cerulean Pharma. "Dr. Fetzer to Highlight Nanopharmaceutical Advancement at BioPharm America Event". AZoNano. 03 October 2024. <https://www.azonano.com/news.aspx?newsID=19548>.

  • Chicago

    Cerulean Pharma. "Dr. Fetzer to Highlight Nanopharmaceutical Advancement at BioPharm America Event". AZoNano. https://www.azonano.com/news.aspx?newsID=19548. (accessed October 03, 2024).

  • Harvard

    Cerulean Pharma. 2019. Dr. Fetzer to Highlight Nanopharmaceutical Advancement at BioPharm America Event. AZoNano, viewed 03 October 2024, https://www.azonano.com/news.aspx?newsID=19548.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.